Cancer Exports Molecular ‘Saboteurs’ to Remotely Disarm Immune System
This article is archived and only made available for historical reference. If you’d like to discover UCSF’s most recent advances in research, education and patient care, please visit the UCSF News Center. But the majority of patients don’t respond to these drugs, and they work far better in some cancers than others, for reasons that have befuddled scientists.
- ▪This article is archived and only made available for historical reference.
- ▪If you’d like to discover UCSF’s most recent advances in research, education and patient care, please visit the UCSF News Center.
- ▪But the majority of patients don’t respond to these drugs, and they work far better in some cancers than others, for reasons that have befuddled scientists.
UCSF News files mainly under design. We currently carry 50 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | UCSF News |
| Canonical URL | https://www.ucsf.edu/news/2019/04/413836/cancer-exports-molecular-saboteurs-remotely-disarm-immune-system |
| Publication time | Thursday, April 4, 2019 - 08:00 |
| Retrieval time | 2026-07-25T19:18:36.544Z |
| Last seen | 2026-07-25T19:18:49.412Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 0e4JgaiJUFDG |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
This article is archived and only made available for historical reference. If you’d like to discover UCSF’s most recent advances in research, education and patient care, please visit the UCSF News Center. Research April 4, 2019 Archive: Cancer Exports Molecular ‘Saboteurs’ to Remotely Disarm Immune System Discovery May Help Explain Immunotherapy Resistance, Hints at New Therapies By Jason Alvarez Share on Facebook Share on Twitter Share on Reddit Email this article Print this article Immunotherapy drugs known as checkpoint inhibitors have revolutionized cancer treatment: many patients with malignancies that until recently would have been considered untreatable are experiencing long-term remissions.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at UCSF News.